Abstract
Considerable advances have been made in the last decade in devising and evaluating cell transplantation strategies for enhancing axon regeneration for patients with spinal cord trauma, and in achieving remyelination in chronic demyelinating diseases such as multiple sclerosis. Thus, a number of studies have established that transplantation of glial cells can have beneficial consequences in experimental models of spinal cord trauma and demyelination. In particular, in rats, it has been shown that implantation of Schwann cells or olfactory glial cells results in significant regeneration of axons across spinal cord transection sites and that this is associated with an improvement of locomotor function (Cheng et al., 1997; Xu et al., 1999; Ramón-Cueto et al., 2000). A potential therapeutic superiority of olfactory glia over Schwann cells was demonstrated by experiments in which the number of regenerating axons crossing a transection site was dramatically increased when olfactory glia were placed at the interface between a Schwann-cell-filled guidance tube and the damaged spinal cord (Ramón-Cueto et al., 1998). The reports of such experiments stimulate considerable media interest and, not unexpectedly, raise patient hopes for a cure to their disability. There is therefore a major challenge for neuroscientists and clinicians to build on the proof of the principle established by these experimental studies with a view to adapting the approach for clinical use.